

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: Protego Medical Pty Ltd

主要联系人姓名: Pablo Solis

主要联系人职务: 首席执行官

公司网址: 不适用

公司地址: Level 9, 278 Collins Street, Melbourne, VIC 3000

公司未上市

公司简介

Protego 医学有限公司(Protego)位于墨尔本, 成立于 2013 年 6 月, 其创办初衷是开发一种新型医学设备。这项设备能够在手术时消除胸骨流血并降低由胸骨牵引器刀片造成创伤, Protego 公司的目标是开发这项设备并将其投入商业运作。该设备的核心技术由一位名叫 Randall Moshinsky 的墨尔本当地心胸外科医生发明。这项发明已经吸引了来自医学研究商业基金(MRCF) 200 万美元的基金支持。其专利已经在 2013 年 11 月发布。

这个公司由一位 CEO 和三位董事组成。这项设备已通过实验室和尸体解剖研究。为测试其安全有效性, 公司正在生产设备, 计划于 2015 年 7 月用于心脏手术, 这将是该设备首次用于人体试验。公司打算两年内在世界主要市场商业推广该项设备。

关键技术或领先技术

在目前的临床实践中, 心脏手术一般使用胸骨牵拉器来固定胸骨边缘, 但这可能导致对胸骨造成创伤, 并且可能引起胸骨碎裂继而增加术后疼痛和发病率。Protego 医学有限公司目前研制的胸骨保护装置 (SPD) 是一种一次性的医学仪器, 可以在切开胸骨的心脏手术中使用, 并减少胸骨流血和碎裂。

开发这一设备所面临的挑战包括面对不同病人的胸骨形状和大小的差异。设备现经设计可适应不同患者, 保护胸骨缘, 预防出血, 同时免受创伤。

该设备由医用级材料制成, 具有良好的生物兼容性, 与胸骨缘轮廓相吻合, 并对其产生压缩力, 由此可以预防出血。设备通过把牵引器刀片的力均匀地分散到胸骨上, 减少胸骨骨折的可能。

类别

设备类：医疗设备和医院用品

关键技术或领先技术的发展阶段

临床前阶段

合作机会

Protego 在 2013 年 10 月，通过 Brandon Capital Partners 赢得了医学研究商业化基金发放的 200 万澳元启动资金。本公司目前寻求多方融资，以期成功完成所有中间步骤，进入目标市场。

在 2016 年，本公司将在主要目标市场寻求潜在的分销商。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: Protego Medical Pty Ltd

Key contact name: Pablo Solis

Job title of key contact: CEO

Company website address: N/A

Company address: Level 9, 278 Collins Street, Melbourne, VIC 3000

The company is Unlisted.

ABOUT THE COMPANY

Protego Medical Pty Ltd (Protego) is a Melbourne-based company incorporated in June 2013 with the purpose of developing a novel medical device. Protego's overall objective is to develop and commercialise a device that eliminates sternal bleeding during the procedure and reduces trauma to the sternum from the sternal retractor blades. The technology behind this device is invented by Dr

Randall Moshinsky, a Melbourne-based cardiothoracic surgeon. The invention has attracted \$2M in funds from the Medical Research Commercialisation Fund (MRCF). A patent over the invention was published in November 2013.

The company has one full time employee, who is the CEO, and three board members. The device has undergone bench top and cadaver studies, and is now being manufactured for the first in human trials, to evaluate its safety and efficacy during cardiac surgery in July 2015. The company is aiming to commercialise the device in major markets across the world within two years.

KEY OR LEAD TECHNOLOGY

In the current clinical practice, the use of sternal retractors to hold back the edges of the sternum in cardiac surgery leads to trauma to the sternum and sometimes sternal fractures resulting in increased post-operative pain and morbidity. The Sternal Protection Device (SPD) that is being developed by Protego Medical Pty Ltd is a single use medical device that is intended to be used during cardiac surgery involving a median sternotomy incision to reduce sternal bleeding and sternal fractures.

The challenge in developing such a device involves addressing the variability in sternal shape and size in different patients. The device has been designed to conform to the individual patient's anatomical variation and provide a cover to the sternal edges which will prevent bleeding and also protect the sternal edges from trauma.

The device is made out of a number of medical grade and biocompatible materials to achieve a contouring and compressive effect on the sternal edges to prevent bleeding and also to evenly distribute the forces from the retractor blades over the length of the sternum to reduce sternal fractures.

Category

Devices: Medical equipment and hospital supplies

Point of development of key or lead technology

Pre-clinical

OPPORTUNITIES SOUGHT

Protego was launched with AU\$2M funds from Medical Research Commercialisation Fund (MRCF) via Brandon Capital Partners in Oct, 2013. The company is currently seeking for more funds from various sources in order to successfully complete all the intermediate steps to enter the target markets.

In 2016 the company will also search for potential distributors in key target markets.